These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 1602394)

  • 21. Direct thrombin inhibitors are not equally effective in vivo against arterial thrombosis: in vivo evaluation of DuP714 and argatroban in a porcine angioplasty model and comparison to r-hirudin.
    McBane RD; Hassinger NL; Mruk JS; Grill DE; Chesebro JH
    Thromb Res; 2005; 116(6):525-32. PubMed ID: 16181988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
    Zhang B; Wieslander JB
    Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
    Heran C; Morgan S; Kasiewski C; Bostwick J; Bentley R; Klein S; Chu V; Brown K; Colussi D; Czekaj M; Perrone M; Leadley R
    Eur J Pharmacol; 2000 Feb; 389(2-3):201-7. PubMed ID: 10688985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time.
    Berry CN; Girard D; Lochot S; Lecoffre C
    Br J Pharmacol; 1994 Dec; 113(4):1209-14. PubMed ID: 7889274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of heparin-resistant microarterial thrombosis by recombinant hirudin: a specific thrombin inhibitor.
    Arnljots B; Bergqvist D
    Plast Reconstr Surg; 1995 Apr; 95(5):894-900. PubMed ID: 7708874
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of a sub-cutaneously administered novel mixed micellar formulation of argatroban in rat and rabbit models of venous thrombosis.
    Berry CN; Visconte C; Lecoffre C; Lochot S; Girard D
    Thromb Haemost; 2000 Aug; 84(2):286-90. PubMed ID: 10959702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of argatroban and heparin on thrombus formation and tissue plasminogen activator-induced thrombolysis in a microvascular thrombosis model.
    Yamada K; Tsuji H; Kimura S; Kato H; Yano S; Ukimura N; Yamada Y; Nakagawa K; Nakagawa M
    Thromb Res; 2003 Jan; 109(1):55-64. PubMed ID: 12679132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative study on the antithrombotic efficacy of hirudin, heparin and a low-molecular weight heparin in preventing experimentally induced venous thrombosis.
    Monreal M; Galego G; Monreal L; Angles AM; Monasterio J; Oller B
    Haemostasis; 1993; 23(3):179-83. PubMed ID: 8276322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of the dosage of recombinant hirudin to inhibit arterial thrombosis in baboons.
    Kotzé HF; Lamprecht S; Van Wyk V; Roodt JP; Badenhorst PN
    J Pharm Sci; 2000 May; 89(5):579-85. PubMed ID: 10756323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons.
    Kelly AB; Marzec UM; Krupski W; Bass A; Cadroy Y; Hanson SR; Harker LA
    Blood; 1991 Mar; 77(5):1006-12. PubMed ID: 1995089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries.
    Tomaru T; Nakamura F; Aoki N; Sakamoto Y; Omata M; Uchida Y
    Heart Vessels; 1996; 11(3):133-44. PubMed ID: 8897062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time.
    Schumacher WA; Heran CL; Steinbacher TE
    J Cardiovasc Pharmacol; 1996 Jul; 28(1):19-25. PubMed ID: 8797131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of napsagatran (Ro 46-6240), a new synthetic thrombin inhibitor and of heparin in a canine model of coronary artery thrombosis: comparison with an ex vivo annular perfusion chamber model.
    Roux S; Tschopp T; Baumgartner HR
    J Pharmacol Exp Ther; 1996 Apr; 277(1):71-8. PubMed ID: 8613969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antithrombotic potency of hirudin is increased in nonhuman primates by fibrin targeting.
    Bode C; Hanson SR; Schmedtje JF; Haber E; Mehwald P; Kelly AB; Harker LA; Runge MS
    Circulation; 1997 Feb; 95(4):800-4. PubMed ID: 9054733
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition by Argatroban, a specific thrombin inhibitor, of platelet activation by fibrin clot-associated thrombin.
    Lunven C; Gauffeny C; Lecoffre C; O'Brien DP; Roome NO; Berry CN
    Thromb Haemost; 1996 Jan; 75(1):154-60. PubMed ID: 8713795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antithrombotic action of recombinant hirudin in a venous thrombosis model.
    Raake W; Klauser RJ; Elling H; Zeiller P
    Haemostasis; 1991; 21 Suppl 1():127-32. PubMed ID: 1654293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin.
    Duval N; Lunven C; O'Brien DP; Grosset A; O'Connor SE; Berry CN
    Br J Pharmacol; 1996 Jun; 118(3):727-33. PubMed ID: 8762100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator.
    Jang IK; Gold HK; Leinbach RC; Fallon JT; Collen D
    Circ Res; 1990 Dec; 67(6):1552-61. PubMed ID: 2123135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study].
    Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL
    Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of argatroban, a direct thrombin inhibitor, and its clinical application.
    Matsuo T; Koide M; Kario K
    Semin Thromb Hemost; 1997; 23(6):517-22. PubMed ID: 9469623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.